sorafenib has been researched along with Experimental Mammary Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, DS; Chen, AF; Chen, XS; Cheng, Y; Guan, YD; Jiang, SL; Yang, JM; Zhang, LX; Zhang, Y | 1 |
| Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L | 1 |
| Danhier, P; Gallez, B; Gregoire, V; Jordan, BF; Magat, J; Masquelier, J; Mignion, L; Muccioli, GG; Porporato, PE; Sonveaux, P | 1 |
| Atkins, MB; Goldberg, SN; Kruskal, JB; Rahmanuddin, S; Raptopoulos, VD; Sabir, A; Schor-Bardach, R; Signoretti, S; Wilcox, CJ | 1 |
| Deblois, F; Devic, S; Heravi, M; Holmes, J; Liang, L; Muanza, T; Radzioch, D; Tomic, N | 1 |
| Brandt, R; Dredge, K; Hammond, E | 1 |
6 other study(ies) available for sorafenib and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epothilones; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib | 2020 |
Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Topics: Animals; Antineoplastic Agents; Choline Kinase; Diffusion Magnetic Resonance Imaging; Female; Heterografts; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protons; Sorafenib; Sulfonamides | 2016 |
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Mammary Neoplasms, Experimental; Niacinamide; Outcome Assessment, Health Care; Perfusion; Phenylurea Compounds; Prognosis; Pyridines; Rats; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; G2 Phase; Gamma Rays; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib | 2012 |